Arbutus Biopharma Corporation
Organization details
- Legal name
- Arbutus Biopharma Corporation
- Former names
- Tekmira Pharmaceuticals Corp
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- British Columbia, Canada
- Headquarters city
- Warminster
- Headquarters state / province
- Pennsylvania
- Headquarters country
- Canada
- Fiscal year end
- December
- Ticker symbol
- ABUS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001447028
- EIN
- 98-0597776
Board of directors
-
Anuj Hasija · DirectorSince 2025
-
Daniel D. Burgess · DirectorSince 2023
-
Frank Torti · DirectorSince 2023
-
James R. Meyers · DirectorSince 2023
-
Joseph E. Bishop · DirectorSince 2025
-
Keith S. Manchester · DirectorSince 2023
-
Lindsay Androski · Director · President and CEOSince 2025
-
Matthew Gline · DirectorSince 2025
-
Melissa Rewolinski · DirectorSince 2023
-
Michael J. McElhaugh · Director · Interim President & CEOSince 2024
-
Richard C. Henriques Jr. · DirectorSince 2023
-
Robert A. Beardsley · DirectorSince 2025
-
Roger Sawhney · DirectorSince 2025
-
William H. Collier · Director · President and CEOSince 2023
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
128.2% a year in revenue
20% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Director election results
Annual meeting of May 26, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
86.5%
-
93.4%
-
93.8%
-
94.5%
-
95.1%
Board connections
7 of this board's directors also sit on 8 other boards.
- via Keith S. Manchester and Matthew Gline
- via Roger Sawhney
- via Roger Sawhney
- via Richard C. Henriques Jr.
- via James R. Meyers
- via Lindsay Androski
- via Frank Torti
- via James R. Meyers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Lindsay Androski Director, Officer (President and CEO) | Option exercise | +116,408 | $3.20 | $372,506 |
| Sep 18, 2026 | Robert A. Beardsley Director | Option exercise | +52,533 | $3.20 | $168,106 |
| Sep 18, 2026 | Roger Sawhney Director | Option exercise | +52,533 | $3.34 | $175,460 |
| Sep 18, 2026 | Nguyen Tuan Officer (Chief Financial Officer) | Option exercise | +265,625 | $3.49 | $927,031 |
| Sep 18, 2026 | Lindsay Androski Director, Officer (President and CEO) | Option exercise | +10,456 | $4.39 | $45,902 |
| Sep 18, 2026 | Robert A. Beardsley Director | Option exercise | +78,800 | $4.24 | $334,112 |
| Sep 18, 2026 | Roger Sawhney Director | Option exercise | +78,800 | $4.24 | $334,112 |
| Sep 18, 2026 | Nguyen Tuan Officer (Chief Financial Officer) | Option exercise | +27,475 | $4.39 | $120,615 |
| Sep 18, 2026 | Lindsay Androski Director, Officer (President and CEO) | Shares withheld for tax | −82,527 | $5.07 | $418,412 |
| Sep 18, 2026 | Robert A. Beardsley Director | Shares withheld for tax | −99,057 | $5.07 | $502,219 |
| Sep 18, 2026 | Roger Sawhney Director | Shares withheld for tax | −100,508 | $5.07 | $509,576 |
| Sep 18, 2026 | Nguyen Tuan Officer (Chief Financial Officer) | Shares withheld for tax | −206,637 | $5.07 | $1,047,650 |
| Feb 2, 2026 | Nguyen Tuan Officer (Chief Financial Officer) | Grant or award | +73,500 | — | — |
| Feb 2, 2026 | Lindsay Androski Director, Officer (President and CEO) | Grant or award | +28,000 | — | — |
| Feb 14, 2025 | Naftzger J. Christopher Officer (General Counsel and CCO) | Grant or award | +54,300 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.